RE:ONCY's Bracelet-1 was in HR+/HER2 negative breast cancer The combination of the oncolytic reovirus pelareorep and paclitaxel generated responses in patients with metastatic hormone receptor (HR)–positive/HER2-negative breast cancer, according to data from the phase 2 BRACELET-1 trial (NCT04215146) presented at the 2023 ASCO Annual Meeting.1,2
Notably, findings also showed that the addition of avelumab (Bavencio) to pelareorep and paclitaxel increased toxicity without an obvious increase in efficacy.
Fever, chills, and/or influenza-like symptoms are normally expected any-grade adverse effects with pelareorep therapy that is normally treated with Tylenol.
https://www.onclive.com/view/pelareorep-plus-paclitaxel-induces-responses-in-metastatic-hr-her2-breast-cancer